EP1178809A1 - Acetylsalicylsaüre und clopidogrel hydrogenosulfat enthaltende pharmazeutische zusammensetzung in einzeldosisform - Google Patents

Acetylsalicylsaüre und clopidogrel hydrogenosulfat enthaltende pharmazeutische zusammensetzung in einzeldosisform

Info

Publication number
EP1178809A1
EP1178809A1 EP00922737A EP00922737A EP1178809A1 EP 1178809 A1 EP1178809 A1 EP 1178809A1 EP 00922737 A EP00922737 A EP 00922737A EP 00922737 A EP00922737 A EP 00922737A EP 1178809 A1 EP1178809 A1 EP 1178809A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
acetylsalicylic acid
clopidogrel
hydrogen sulfate
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00922737A
Other languages
English (en)
French (fr)
Inventor
Bernard Abramovici
Jean Lheritier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of EP1178809A1 publication Critical patent/EP1178809A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • composition in unit form containing acetylsalicylic acid and clopidogrel hydrogen sulfate
  • the present invention relates to a pharmaceutical composition in a unit dosage form containing an association of active principles with antiplatelet activity consisting of acetylsalicylic acid, also known under the brand name Aspirin, and clopidogrel hydrogen sulfate.
  • the unit dosage form can be administered orally and preferably consists of a tablet, a capsule or a dose sachet.
  • acetylsalicylic acid is used in its acid form and clopidogrel hydrogen sulphate can be used in the form of one or other of its polymorphs known to date and called Form 1 (F1) or Form 2 (F2).
  • Form 1 is the salt described in patent EP 281459 and clopidogrel hydrogen sulfate Form 2 is that described in patent application FR 98 07464.
  • the therapeutic advantage of the combination of acetylsalicylic acid and of clopidogrel is among others described in patent application WO 97/29753.
  • compositions are mentioned there without ever specifying that the pharmaceutically acceptable salt used is clopidogrel hydrogen sulfate. This document always indicates that the composition can be used parenterally or orally and that it is possible to administer the active ingredients according to four modes of administration, namely, both orally, both parenterally or one orally and the other parenterally or vice versa.
  • the tablets according to the invention can be obtained by various manufacturing processes such as for example:
  • the direct compression process in which the active ingredients and the selected excipients are mixed.
  • the mixture obtained is sieved (calibrated) on a previously defined mesh opening grid, in order to homogenize the particle sizes of the constituents.
  • a new mixing is carried out to ensure good homogeneity of the active ingredients.
  • Specific excipients (example: a flow agent) as well as a lubricant are added and mixed.
  • the final mixture obtained is then compressed.
  • Dry granulation consists in ensuring that the active ingredients and the selected excipients are mixed, calibrated and then mixed again.
  • the mixture is forced between two mobile cylinders, in opposite directions of rotation, in order to obtain, according to the forces exerted, plates of determined mechanical strengths. These plates are calibrated.
  • the specific excipients are added and the final mixture compressed.
  • Hot melt granulation is a granulation process that can be used when an active ingredient degrades in the presence of water.
  • the active ingredients and the selected excipients are calibrated and then mixed.
  • the mixture is brought under slow stirring to a temperature slightly higher than that of the melting point of the excipient, mixed under rapid stirring, then cooled to room temperature.
  • the grain obtained is calibrated.
  • the specific excipients are added and the final mixture compressed.
  • An example of a "hot melt” process in a granulator with a fluidized air bed is described below.
  • the active ingredients and the selected excipients, except the fusible excipient are calibrated and then transferred to a granulator with a fluidized air bed.
  • the whole is mixed by fluidization with supply of hot air, up to a temperature of the mixture slightly lower than that of the melting point of the granulation excipient.
  • the molten excipient is then sprayed onto the fluidized mixture.
  • the temperature of the fluidizing air is lowered.
  • the grain obtained is calibrated.
  • the specific excipients are added and the final mixture compressed.
  • the capsules and dose sachets are prepared according to techniques well known to those skilled in the art.
  • the pharmaceutical compositions according to the invention are used for the treatment of a pathology induced by platelet aggregation including stable or unstable angina, disorders of the cardiovascular and cerebrovascular system such as thromboembolic disorders associated with atherosclerosis and diabetes such as unstable angina, cerebral attack, restenosis after angioplasty, endarterectomy or fitting of metal endovascular prostheses or thromboembolic disorders associated with rethrombosis after thrombolysis, infarction, dementia of ischemic origin, peripheral arterial diseases, hemodialysis, atrial fibrillation or even when using vascular prostheses, bypass surgery, or during radiotherapy to reduce side effects.
  • compositions according to the invention are used for the preparation of a medicament intended for the treatment of the pathologies mentioned above and allow the treatment of these pathologies.
  • clopidogrel hydrogen sulfate and acetylsalicylic acid are present in a molar ratio of clopidogrel hydrogenosulfate / acetylsalicylic acid comprised between 2.5 and 11, preferably between 5 and 9.
  • clopidogrel hydrogen sulfate 1 to 500 mg per day of clopidogrel hydrogen sulfate and 1 to 500 mg per day of acetylsalicylic acid are administered to humans, the doses being expressed in equivalent amounts of clopidogrel in free form.
  • clopidogrel hydrogen sulfate is administered and 75 to
  • compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 75 mg of acetylsalicylic acid are particularly preferred.
  • compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 375 mg of acetylsalicylic acid Preference is also given to compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 375 mg of acetylsalicylic acid.
  • Example granulation process by compacting
  • Anhydrous lactose ⁇ can be replaced in an equivalent amount with mannitol.
  • Example granulation process by compacting
  • Mannitol can be replaced in an equivalent amount by anhydrous lactose ⁇ .
  • a) 97.875 g of clopidogrel hydrogenosulfate are mixed with 2 g of anhydrous colloidal silica b) 325 g of acetylsalicylic acid, 30 g of corn starch, 124.6 g of mannitol and 60 g of microcrystalline cellulose are added to a) and mixed c)
  • the mixture b) is calibrated and then mixed again d) 10.5 g of hydrogenated castor oil are added to c) before the final mixture e)
  • the final mixture is compressed to a theoretical unit mass of 650 mg
  • the mixture is made in mini-rhôn for 10 minutes between the active ingredients and the diluents.
  • the active ingredients are mixed with the mini-rhôn for 10 minutes with the diluents.
  • Anhydrous colloidal silica is added to the above mixture and then sieved through a grid of 0.315 mm mesh opening.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP00922737A 1999-04-30 2000-04-25 Acetylsalicylsaüre und clopidogrel hydrogenosulfat enthaltende pharmazeutische zusammensetzung in einzeldosisform Withdrawn EP1178809A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905497 1999-04-30
FR9905497A FR2792836B3 (fr) 1999-04-30 1999-04-30 Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
PCT/FR2000/001086 WO2000066130A1 (fr) 1999-04-30 2000-04-25 Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel

Publications (1)

Publication Number Publication Date
EP1178809A1 true EP1178809A1 (de) 2002-02-13

Family

ID=9545071

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00922737A Withdrawn EP1178809A1 (de) 1999-04-30 2000-04-25 Acetylsalicylsaüre und clopidogrel hydrogenosulfat enthaltende pharmazeutische zusammensetzung in einzeldosisform

Country Status (24)

Country Link
EP (1) EP1178809A1 (de)
JP (1) JP2002543137A (de)
KR (1) KR20020005735A (de)
CN (1) CN1359294A (de)
AR (1) AR023789A1 (de)
AU (1) AU4303600A (de)
BR (1) BR0010194A (de)
CA (1) CA2371231A1 (de)
CZ (1) CZ20013887A3 (de)
EA (1) EA200100959A1 (de)
EE (1) EE200100559A (de)
FR (1) FR2792836B3 (de)
HK (1) HK1041823A1 (de)
HU (1) HUP0202329A2 (de)
IL (1) IL145648A0 (de)
IS (1) IS6084A (de)
MX (1) MXPA01011071A (de)
NO (1) NO20015295L (de)
NZ (1) NZ514248A (de)
PL (1) PL351923A1 (de)
SK (1) SK15542001A3 (de)
TR (1) TR200103039T2 (de)
UY (1) UY26131A1 (de)
WO (1) WO2000066130A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526540A (en) 2000-12-25 2004-11-26 Sankyo Co Medicinal compositions containing aspirin and 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine useful in preventing thrombus or embolus diseases
RU2180848C1 (ru) * 2001-01-30 2002-03-27 Плотников Марк Борисович Средство с антиагрегантной и гемореологической активностью
US6767913B2 (en) 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US7074928B2 (en) 2002-01-11 2006-07-11 Teva Pharmaceutical Industries, Ltd. Polymorphs of clopidogrel hydrogensulfate
IL166593A0 (en) 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel
US6800759B2 (en) 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
JP4917255B2 (ja) * 2003-10-16 2012-04-18 第一三共ヘルスケア株式会社 サリチル酸類含有経口組成物
WO2005070464A2 (en) * 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
KR20070044323A (ko) * 2005-10-24 2007-04-27 에스케이케미칼주식회사 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제
EP2001449A2 (de) * 2006-04-05 2008-12-17 Cadila Healthcare Ltd. Clopidogrelformulierung mit modifizierter freisetzung
EP1900358A1 (de) * 2006-09-16 2008-03-19 Cimex Pharma AG Clopidogrel enthaltende Arzneiformulierungen
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
JP2011512406A (ja) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド 複合製剤
CN101695496A (zh) * 2009-10-15 2010-04-21 苏春华 一种含有三氟柳和氯吡格雷的药物组合物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
RU2484820C2 (ru) * 2011-02-24 2013-06-20 Общество с ограниченной ответственностью "Озон" Комбинированное лекарственное средство, являющееся ингибитором агрегации тромбоцитов
KR101675501B1 (ko) 2011-11-02 2016-11-14 한국유나이티드제약 주식회사 클로피도그렐 및 아스피린의 복합제제
CN102406938A (zh) * 2011-11-29 2012-04-11 北京阜康仁生物制药科技有限公司 一种抗血栓的药物组合物
JP6004524B2 (ja) * 2012-07-11 2016-10-12 大原薬品工業株式会社 クロピドグレル硫酸塩含有錠剤の製造方法
JP5905165B2 (ja) * 2013-08-02 2016-04-20 サノフイ アセチルサリチル酸およびクロピドグレルを含む医薬錠剤
CN104434932B (zh) * 2014-12-18 2017-05-24 成都苑东生物制药股份有限公司 一种硫酸氢氯吡格雷阿司匹林片药物组合物及其制备方法
WO2017037741A1 (en) * 2015-09-02 2017-03-09 Sun Pharmaceutical Industries Ltd Compact solid dosage form of aspirin and clopidogrel
CN115737578A (zh) * 2022-11-23 2023-03-07 石家庄四药有限公司 一种硫酸氢氯吡格雷阿司匹林复方片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0066130A1 *

Also Published As

Publication number Publication date
HK1041823A1 (zh) 2002-07-26
NO20015295D0 (no) 2001-10-29
EE200100559A (et) 2003-02-17
AU4303600A (en) 2000-11-17
EA200100959A1 (ru) 2002-06-27
FR2792836B3 (fr) 2001-07-27
PL351923A1 (en) 2003-06-30
KR20020005735A (ko) 2002-01-17
SK15542001A3 (sk) 2002-02-05
UY26131A1 (es) 2000-12-29
CZ20013887A3 (cs) 2002-02-13
HUP0202329A2 (en) 2002-10-28
AR023789A1 (es) 2002-09-04
TR200103039T2 (tr) 2002-01-21
BR0010194A (pt) 2002-02-13
CN1359294A (zh) 2002-07-17
JP2002543137A (ja) 2002-12-17
NO20015295L (no) 2001-12-21
MXPA01011071A (es) 2002-07-22
WO2000066130A1 (fr) 2000-11-09
IL145648A0 (en) 2002-06-30
NZ514248A (en) 2003-06-30
IS6084A (is) 2001-09-25
CA2371231A1 (en) 2000-11-09
FR2792836A1 (fr) 2000-11-03

Similar Documents

Publication Publication Date Title
EP1178809A1 (de) Acetylsalicylsaüre und clopidogrel hydrogenosulfat enthaltende pharmazeutische zusammensetzung in einzeldosisform
US5980942A (en) Zero-order sustained release matrix tablet formulations of carbamazepine
RU2240795C2 (ru) Фармацевтические композиции противотуберкулезных лекарственных средств и способ их изготовления
EP0330532B1 (de) Neue galenische Form von Fenofibrat
JP2720932B2 (ja) 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤
US6180138B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
JP5714492B2 (ja) 粒状体、それらの調製方法、およびそれらを含む医薬品
RU2238087C2 (ru) Композиции контролируемого высвобождения, содержащие нимесулид
FR2460667A1 (fr) Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide
EP1108424B2 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
PL200957B1 (pl) Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
FR2585570A1 (fr) Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue
FR2561524A1 (fr) Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage
JPH09500910A (ja) パラセタモール及びドンペリドンのフィルムコーティング錠
EP1353663B1 (de) Fenofibrattabletten
EP2814465B1 (de) Pharmazeutische formulierung mit erhöhter stabilität
JP2014012660A (ja) ロキソプロフェン含有医薬組成物
FR2489146A1 (fr) Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide
CA2329232C (en) Stable compositions comprising levosimendan and alginic acid
KR20100041780A (ko) 옥스카르바제핀을 포함하는 방출 제어형 고체 제제의 제조 방법 및 그에 의해 얻어질 수 있는 제제
EP2946771B1 (de) Wasserdispergierbare tablettenformulierung mit deferasirox
JP2000516601A (ja) 水溶性化合物及びセルロースを含有する粒状物
EP0483320B1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren
FR2541576A1 (fr) Medicament contenant de la muzolimine et son procede de preparation
JPH0251527B2 (de)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011130;LT PAYMENT 20011130;LV PAYMENT 20011130;MK PAYMENT 20011130;RO PAYMENT 20011130;SI PAYMENT 20011130

17Q First examination report despatched

Effective date: 20020208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030822

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1041823

Country of ref document: HK